Genetic linkage of FcγRIIa and FcγRIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy

Clinical Lymphoma and Myeloma

Volumn 7, Issue 4, 2007, Pages 286-290

  Hatjiharissi, Evdoxia ^a,b   Hansen, Mark ^a   Santos, Daniel Ditzel ^a   Xu, Lian ^a   Leleu, Xavier ^a,b   Dimmock, Elizabeth W ^a   Ho, Allen W ^a   Hunter, Zachary R ^a   Branagan, Andrew R ^a   Patterson, Christopher J ^a   Kortsaris, Alexandros ^b   Verselis, Sigitas ^a   Fox, Edward ^a   Treon, Steven P ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

CD16; CD32; Fc receptors; Polymorphisms; Rituximab

Indexed keywords

CD20 ANTIBODY; FC GAMMA RECEPTOR 2A; FC GAMMA RECEPTOR 3A; FC RECEPTOR; GENOMIC DNA; HISTIDINE; IMMUNOGLOBULIN G1; RITUXIMAB; UNCLASSIFIED DRUG; VALINE;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG RECEPTOR BINDING; FEMALE; GENETIC LINKAGE; GENETIC POLYMORPHISM; HUMAN; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PREDICTION; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 33947159739     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.004     Document Type: Article

References (25)

1. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6:443-446.
2. Sampson JH, Crotty LE, Lee S, et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci USA 2000; 97:7503-7508.
3. Yoneto T, Waki S, Takai T, et al. A critical role of Fc receptor-mediated antibody-dependent phagocytosis in the host resistance to blood-stage Plasmodium berghei XAT infection. J Immunol 2001; 166:6236-6241.
4. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101:949-954.
5. Grundy HO, Peltz G, Moore KW, et al. The polymorphic Fc gamma receptor II gene maps to human chromosome 1q. Immunogenetics 1989; 29:331-339.
6. de Wit TP, Suijkerbuijk RF, Capel PJ, et al. Assignment of three human high-affinity Fc gamma receptor I genes to chromosome 1, band q21.1. Immunogenetics 1993; 38:57-59.
7. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275-290.
8. de Haas M, Koene HR, Kleijer M, et al. A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa. J Immunol 1996; 156:3948-3955.
9. Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independendy of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90:1109-1114.
10. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997; 100:1059-1070.
11. Hatjiharissi E, Santos DD, Xu L, et al. Individuals expressing FcgRIIIA-158 V/V and V/F show increased NK cell surface expression of FcgRIIIA (CD16), rituximab binding, and demonstrate higher levels of ADCC activity in response to rituximab. Blood 2005; 106:229a (Abstract #776).
12. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-758.
13. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-3947.
14. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005; 23:474-481.
15. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48:455-459.
16. Kim DH, Jung HD, Kim JG, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lyraphoma. Blood 2006; 108:2720-2725.
17. Warmerdam PA, van de Winkel JG, Gosselin EJ, et al. Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). J Exp Med 1990; 172:19-25.
18. Warmerdam PA, van de Winkel JG, Vlug A, et al. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol 1991; 147:1338-1343.
19. Parren PW, Warmerdam PA, Boeije LC, et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest 1992; 90:1537-1546.
20. Farag SS, Flinn IW, Modali R, et al. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004; 103:1472-1474.
21. van der Pol WL, Jansen MD, Sluiter WJ, et al. Evidence for non-random distribution of Fcgamma receptor genotype combinations. Immunogenetics 2003; 55:240-246.
22. Lehrnbecher T, Foster CB, Zhu S, et al. Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood 1999; 94:4220-4232.
23. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591-6604.
24. Presta LG, Shields RL, Namenuk AK, et al. Engineering therapeutic antibodies for unproved function. Biochem Soc Trans 2002; 30:487-490.
25. Bowles JA, Wang SY, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006; 108:2648-2654.